What We Do
Housey Pharmaceutical Research Laboratories (“Housey Pharma”) and Housey Healthcare ULC (“Housey Healthcare” Canada) are private corporations whose business model has been carefully designed and implemented toward a long-term, conservative growth strategy. We have worked hard to develop the next generation business model for creating and developing patient-oriented, patent-protected, cost-effective new medicines and nutritional products. Our model is fundamentally changing the manner in which pharma products are created and developed.
We utilize private funds and operating revenues to grow the company and to fund our research laboratory activities in order to further the development of our new technologies and for new pharmaceutical product discovery. We also receive grant funding for certain projects. By focusing on our business model to produce consistent cash flows, we are able to remain internally funded to sustain our operations.
Although this business strategy is substantially more difficult than pursuing traditional venture capital sources, we believe that it is and will continue to be a key element of our success and an asset for our company that provides several important benefits. First, it allows us to retain our long-term focus on important but often very difficult pharma research projects. We are able to concentrate our efforts on new drug discovery and creation, as well as technology development, while being minimally affected by frequently volatile world economic or social conditions or irrational fluctuations of the public equity markets. For example, neither the 2008 severe recession nor the Covid-19 pandemic have had a significant effect on our operations. Second, it allows us to attract and retain outstanding individuals who wish to develop their careers within an innovative atmosphere that is open, creative, and transparent, yet conservatively run from a financial perspective. This enables us to take substantial scientific risk in order to achieve formidable advances in medical research.
The company or its affiliated entities aggressively pursue patent protection for all new drugs or research technologies created or discovered in its laboratories. These patent-protected drug discoveries may then be commercialized through a variety of approaches including partnering with other pharma industry members.